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ABSTRAK 
 
`Metaplastic breast carcinoma’ (MBC) adalah jenis kanser payu dara yang amat jarang 
ditemui yang dari segi histologinya, bercirikan karsinoma yang terdiri daripada dua 
jenis epitelia atau kehadiran karsinoma bersama-sama dengan elemen ‘bukan-
epitelial’. Ianya adalah agresif dan mempunyai ciri prognosis yang buruk. Ciri-ciri  
patologikal dan klinikal kanser ini dikalangan pesakit kanser payu dara di Pusat 
Perubatan Universiti Kebangsaan Malaysia (PPUKM) telah dikaji dari tahun 2000 
sehingga 2007. Daripada 471 pesakit kanser payu dara di PPUKM terdapat enam  
pesakit wanita dikenal pasti melalui diagnosis histologi mengidap MBC yang mana 
ianya melibatkan 1.3% dari keseluruhan kes kanser payu dara. Empat daripada 
mereka adalah dari etnik Melayu manakala dua adalah India dan min umur mereka 
adalah 51 tahun. Di dalam kesemua kes, kanser ini adalah besar, bersaiz lebih dari 5 
sm, gred 3 dan bereseptor estrogen negatif. Lima pesakit menjalani mastectomi 
(empat bersama ‘axillary clearance’ manakala satu tanpa ‘axillary clearance’). 
Penglibatan kelenjar limfa aksilari didapati pada empat pesakit (tiga pesakit 
mempunyai tumor jenis epithelia sahaja dan satu tumor dwifasa). Lima pesakit 
menerima kemoterapi, seorang lagi enggan dirawat secara kemoterapi. Kesemua 
pesakit mengalami rekuren tumor dengan min masa rekuren selama 9 bulan. 
Kesimpulannya, MBC  jarang berlaku, agresif dan biasanya melibatkan golongan 
wanita yang sudah menopos. Mereka selalunya bersaiz besar, mempunyai gred 
histopatologi tinggi dan bereseptor estrogen negatif. Saiz tumor yang besar serta 
perebakan tumor ke kelenjar limfa menjangkakan prognosis buruk. Walaupun dengan 
rawatan kemoterapi dan radioterapi, pesakit-pesakit ini mempunyai risiko yang tinggi 
untuk mendapat kanser berulang atau merebak ke organ lain. 
 
Kata kunci:  kanser metaplastik payu dara, ciri-ciri patologikal, kesan klinikal 
 
 
ABSTRACT  
 
Metaplastic breast carcinomas (MBCs) are rare primary breast malignancies 
characterized histologically by carcinoma of two epithelial types or co-existence of 
carcinoma with non-epithelial cellular elements. They are aggressive tumours that 
carry poor prognosis. We reviewed the pathologic features and clinical outcomes of 
MBCs seen in our institution between the years 2000 to 2007. Out of 471 breast
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cancer patients, six female patients were histologically-proven to have MBCs giving an 
incidence rate of 1.3%. The patients comprised four Malays and two Indians and their 
mean age was 51 years old.  Five patients underwent mastectomy (four with axillary 
clearance and one without) and one had wide local excision with axillary clearance. 
Axillary lymph node involvement was seen in four patients (three with epithelial only 
type tumour and one with the biphasic tumour). In all the cases, the tumours were 
bigger than 5 cm in diameter (T3), grade 3 and estrogen receptor negative. Five 
patients received chemotherapy while one refused. All of the patients had tumour 
recurrence with a mean time of recurrence of 9 months. In conclusion, metaplastic 
breast carcinomas are rare and aggressive tumours usually affect the post 
menopausal age group. They present as aggressive, large sized, high grade tumours 
that are estrogen receptor negative. Tumour size and axillary lymph node involvement 
indicate poor prognosis. Despite treatment with chemotherapy and radiotherapy, these 
patients have high risk of local recurrence and distant metastases which are potentially 
fatal. 
 
Key words:  metaplastic breast carcinomas, pathologic features, outcome 
 
 
 
INTRODUCTION  
 
Metaplastic breast carcinomas (MBCs) 
encompass a heterogeneous group  of 
breast cancers characterised histologi-
cally by intimate admixture of adenocar-
cinoma with dominant areas of spindle 
cell, squamous, and/or mesenchymal 
differentiation (Devilee & Tavasoli 2003). 
The tumour may present in pure form of 
metaplastic spindle cell or squamous cell 
component without recognizable adeno-
carcinoma. It can be categorised into 
purely epithelial (when it is composed of 
squamous cell carcinoma only or adeno-
carcinoma and squamous cell) or mixed 
epithelial and mesenchymal e.g. carcino-
sarcoma. These tumours are rare, ac-
counting for less than 1% of all breast 
cancer cases with mean age of presen-
tation at 55 years old (Devilee &Tavasoli  
2003). Between 1984 to 2005, there were 
only 16 published reports of 505 cases 
discussing the clinical and pathological 
characteristics of this tumour (Beatty et 
al. 2006). Due to its rarity, data on the 
current understanding and management 
of metaplastic breast carcinomas are 
scanty. We report our experience in 
managing six cases of metaplastic breast 
carcinomas encountered at our centre 
over an 8-year study period. The histo-
pathological features and clinical out-
comes from these patients are reviewed.  
 
MATERIALS AND METHODS 
 
Cases were retrieved from the Breast 
Cancer Database at The Breast and En-
docrine Unit, Universiti Kebangsaan Ma-
laysia Medical Center (UKMMC). Infor-
mation on the demographics, diagnosis, 
tumour grade, oestrogen (ER) and 
progesterone (PR) receptors status, 
HER2 expression, clinical staging, treat-
ment, recurrence status and patient sur-
vival was recorded. Information on the 
patients’ survival details were obtained 
from the medical records and through 
telephone conversations with their family 
members. The patients were grouped 
according to tumour types; epithelial and 
biphasic histological subtypes. Disease 
free survival was defined as the time 
from diagnosis to distant recurrence (or 
death from cancer in the absence of re-
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currence) or last follow-up. Overall sur-
vival was defined as the time from diag-
nosis to the time of death from the cancer 
or date of last contact for patients who 
are still alive or who had died from other 
causes. 
 
RESULTS 
 
A total of 471 breast cancer patients 
were operated between 2000 and 2007 
at our institution, of which six female pa-
tients were histologically confirmed to 
have MBCs, giving an incidence rate of 
1.3%. Ethnically, the patients comprised 
four Malays and two Indians. The mean 
age of our patients was 51 years with the 
epithelial only group being slightly 
younger age (42 years) than the biphasic 
group (55 years). The mean tumour size 
was 9.5cm with the epithelial only group 
presenting with slightly bigger tumor size 
(13cm) compared to the biphasic group 
(8 cm). Histologicaly, three of the six pa-
tients had epithelial only tumours com-
posed of both adenocarcinoma and 
squamous cell carcinoma while the other 
three patients were diagnosed with tu-
mours of the biphasic type expressing 
both carcinoma and sarcomatoid compo-
nents. All patients had grade 3 tumours 
and all tumours were ER and PR 
negative. Only four patients had the 
HER2 status tested, all of which were 
negative. Axillary nodal involvement was 
found in all epithelial only group and one 
in the biphasic group.  Four patients 
underwent mastectomy with axillary 
clearance, one patient had mastectomy 
only and one had wide local excision with 
axillary clearance. Two patients received 
neoadjuvant chemotherapy while another 
three had adjuvant chemotherapy. One 
patient refused chemotherapy. All of the 
patients had tumour recurrence with 
mean time of recurrence of 9 months. 
Five of them died two to three months 
after tumour recurrence. Table 1 summa-
rises the relevant clinicopathological 
findings.  
 
Table 1 :  Summary of metaplastic breast cancer cases 
 
Patient 
No. 
Tumour 
grade 
ER PR 
No of 
lymph 
nodes 
involved 
Operation 
date 
Type of 
operation 
Chemo- 
therapy 
Recurrence 
date & site 
Death 
1 3 negative negative 12/28 15.01.05 
Mastectomy 
+AC 
Yes 
12.09.05 
local 
07.10.05 
2 3 negative negative 1/31 15.10.02 
Mastectomy 
+AC 
No 
07.05.03 
brain 
17.06.03 
3 3 negative negative 1/8 28.03.03 
Mastectomy 
+AC 
Yes 
May - 2004 
bone 
still alive 
 
4 
3 negative negative 0/7 26.02.05 WLE + AC Yes 
30.09.05 
liver 
31.10.05 
5 3 negative negative - 15.06.02 Mastectomy Yes 
Aug – 2002 
bone 
09.10.02 
6 3 negative negative 0/12 06.08.02 
Mastectomy 
+ AC 
Yes 
July – 2004 
lung, liver 
05.08.04 
ER: estrogen receptor; PR: progesterone receptor; AC: axillary clearance; WLE : wide local excision 
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DISCUSSION 
 
Metaplastic breast carcinomas (MBCs) 
are rare types of breast cancer which are 
difficult to diagnose clinically as they do 
not have specific imaging patterns. They 
are also challenging to the pathologists 
as the tumours have a wide range of 
histopathological features and the 
metaplastic area may dominate the 
whole tumour or occupy a very small 
area within the lesion. In this report, we 
identified six metaplastic breast 
carcinomas and evaluated their 
clinicopathological parameters. We 
record an incidence rate of 1.3% which 
concurs with the reported incidence of 1-
2% elsewhere (Roses 2005). Interes-
tingly, the six patients in our series were 
comprised of four Malay and two Indian 
ethnicity with no MBC diagnosed among 
Chinese patients. Similar ethnic differ-
ences in risks for MBCs was reported in 
an earlier study which reported a higher 
percentage of MBCs among African 
Americans or Hispanics (Pezzi et al. 
2007). The reason for this observation is 
unclear but probably suggests that racial 
or genetic factors may underlie the in-
creased risk for MBCs.  
MBCs were thought to have either ori-
ginated as a single entity or clone that 
originates in the myoepithelial cells or its 
precursor, or those arising from pre-ex-
isting lesions such as papillomas, com-
plex sclerosing lesions and nipple ade-
noma (Denley et al. 2000; Gobbi et al. 
2003; Popnikolov et al. 2003; Reis-Filho 
et al. 2003). This has been further sup-
ported by the fact that these neoplastic 
cells express vimentin, smooth muscle 
actin, muscle specific actin and p63 that 
are commonly associated with myoepi-
thelial cells (Schnitt & Collins 2008). 
Cytokeratin positivity is seen in the epi-
thelial and mesenchymal component of 
this tumour and it is thought that it is the 
metaplasia of the epithelial elements of a 
carcinoma that could have given rise to 
the sarcomatous changes (Saxena et al. 
2004). 
In most literatures, MBCs are ER and 
PR negative, as was the case in all pa-
tients reported here (Kuo et al. 2000; 
Khan et al. 2003; Luini et al. 2007; Pezzi 
et al. 2007). Similarly, most of the MBCs 
in our series did not express HER2 which 
is in keeping with a previous study 
(Barnes et al. 2005). The reported inci-
dences of lymph node involvement in 
these tumors were between 8%-56% 
(Kurian & Al-Nafussi 2002; Khan et al. 
2003). In this series of cases, axillary 
nodal involvement was found in the entire 
epithelial only group and only one of the 
patients in the biphasic group had nodal 
metastases. The distinctive lymph node 
negativity was observed in the presence 
of spindle cell component which may be 
due to the nature of sarcoma that tends 
to metastasize haematogenously rather 
than through lymphatic channels (Sneige 
et al. 2001; Gobbi et al. 2003). Despite 
the lower incidence of axillary lymph 
node involvement, these tumours had 
high metastatic potential either locally, to 
distant organs or both, in more than 50% 
of cases (Wargotz et al. 1989; Wargotz & 
Norris 1989a; Rayson et al. 1999). Most 
distant metastases involve lung or bone 
(Wargotz et al. 1989; Wargotz & Norris 
1989b; Kurian & Al-Nafussi 2002). In our 
series, we had five patients with distant 
metastases and one local recurrence 
(Table 1). 
The average size of the tumours in this 
series was 9.5cm which was bigger than 
the usual size of infiltrating ductal carci-
nomas. This is most likely due to the ag-
gressive nature of the tumours with rapid 
growth rates. Most of these patients had 
poorly differentiated or undifferentiated 
tumours (compared to infiltrating ductal 
carcinoma) which will further lead to rapid 
growth rates (Pezzi et al. 2007). We were 
unable to do a statistical analysis on 
whether the epithelial only group tumours 
were larger than the biphasic group due 
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to the limited number of cases. However, 
in this series the mean tumour size for the 
epithelial group was greater than the 
biphasic group. Five of our patients had 
mastectomy due to the large size of the 
tumours. Five of the patients had systemic 
therapy (one refused) and most of them 
died within a year after surgery. In our 
series, the mean time of recurrence was 9 
months and survival after recurrence was 
short. This concurs with other studies that 
showed that MBCs are less responsive to 
therapy with the conventional regimes that 
are usually used for infiltrating ductal 
carcinoma (Wargotz & Norris 1989a; 
Rayson et al. 1999). There is no survival 
advantage either with chemotherapy or 
radiotherapy for distant metastases 
(Wargotz & Norris 1989a). The median 
survival after metastases is 8 months after 
systemic treatment (Rayson et al. 1999). 
This means that the optimal systemic 
therapy for metaplastic breast carcinoma 
still needs further defining. 
  
CONCLUSION 
 
Metaplastic breast carcinomas are rare 
types of breast cancers usually affecting 
the post menopausal age group. These 
tumours have aggressive clinical beha-
viour, present with locally advanced dis-
ease, are large in size, high grade tu-
mours and triple negative. Despite treat-
ment with chemotherapy and radiothe-
rapy, the patients have a high risk of local 
recurrence and distant metastases which 
are potentially fatal. 
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